In this video, Mhairi Copland, MB ChB, PhD, University of Glasgow, Glasgow, UK, gives an overview of treatment options for patients with chronic myeloid leukemia (CML), including ponatinib, asciminib, and bosutinib. Dr Copland also discusses clinical trials exploring the safety and efficacy of these agents, including the OPTIC trial (NCT02467270), and briefly highlights other novel agents being explored in the field. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
M.C. has received research funding from Cyclacel and Incyte, is/has been an advisory board member for Novartis, Incyte, Jazz Pharmaceuticals, Pfizer and Servier, and has received honoraria from Astellas, Novartis, Incyte, Pfizer and Jazz Pharmaceuticals.